Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth - 2Israeli president concerned over proposed renaming of park
- 3EU calls on Western Balkans to step up reforms for membership
- 4Police break up illegal chicken slaughter in Germany
- 5What's your biological age? Experts explain the benefits and risks of at-home tests
- Manhunt for Brown University shooter continues: FBI releases photos of suspect, announces $50K reward
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- Hot Electric Vehicles for 2023
- Vote In favor of Your Favored Treat
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- Brazil approves law strengthening protective measures for female victims of gender-based violence
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- German foreign minister backs abandoning EU's unanimity principle
